ectoin + xylometazoline

**ectoin + xylometazoline** is a combination therapy used primarily for the symptomatic treatment of **acute rhinosinusitis** and possibly other upper respiratory tract diseases involving nasal inflammation and congestion. - **Ectoin** is a natural, cyclic amino acid derivative that acts via **preferential exclusion**, stabilizing cell membranes and proteins by promoting preferential hydration, thereby protecting mucosal surfaces from environmental stress. It serves as a physical, moisturizing barrier and reduces dehydration of the nasal mucosa[1]. - **Xylometazoline** is a small molecule **alpha-adrenergic agonist** that acts as a topical nasal decongestant by vasoconstricting blood vessels in the nasal mucosa, leading to reduced swelling and improved nasal airflow[3]. - The combination is often applied as **consecutive or concomitant nasal sprays**, not necessarily as a single co-formulated product, but as simultaneous or coordinated use of both agents[1][2][4]. - Clinical studies suggest that the addition of ectoin to xylometazoline improves tolerability, reduces nasal mucosa dryness (a common side effect of decongestant use), and allows for lower xylometazoline dosing while maintaining efficacy in symptom management[1][2]. - This combination is primarily categorized as a **medical device therapy** in Europe, especially for ectoin, but xylometazoline is regulated as a pharmaceutical drug[1][2].

Brand names

Ectoin Rhinitis Nasal Spray

Other names

Ectoin Rhinitis Nasal Spray + xylometazoline